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ABSTRACT
Background: To evaluate the epidemiology of patients who require mechanical ventilation during hyper-
baric oxygen therapy.
Materials and methods: One-hundred-fifty patients who required mechanical ventilation during hyperbaric 
oxygen therapy were prospectively studied during a 6-year period in a French university hyperbaric centre. 
We analysed the indication of hyperbaric oxygen therapy, agent used for sedation, presence of a chest 
tube, need for vasopressor agents and tolerance and appearance of side effects. Finally, we compared the 
outcomes of patients according to the presence or absence of acute respiratory distress syndrome (ARDS).
Results: Eleven children and 139 adult patients were included (n = 150) in the study. In both populations, 
carbon monoxide poisoning (51%) and iatrogenic gas embolism (33%) were the two main causes of intu-
bation and mechanical ventilation. The combination of midazolam and sufentanil was used in 85 (67%) 
patients. All of the patients were given a bolus of a neuromuscular blocker during the hyperbaric session, 
despite the presence of ARDS in 35 patients. Patient-ventilator asynchrony was the most frequent side 
effect in 6 (5%) patients and was often the consequence of suboptimal sedation. Mortality was higher in 
the group with ARDS (23%).
Conclusions: Carbon monoxide poisoning and iatrogenic gas embolism are the two main diseases of the 
patients who required mechanical ventilation during hyperbaric oxygen therapy in this study. Mechanical 
ventilation is a safe method for patients during hyperbaric oxygen therapy. Sedation needs to be perfected 
to avoid patient-ventilator asynchrony.
(Int Marit Health 2017; 68, 1: 46–51)
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INTRODUCTION
Hyperbaric oxygen therapy (HBOT) is the main treat-
ment for many diseases, such as carbon monoxide (CO) 
poisoning, gas embolism or severe soft tissue infections 
[1, 2]. The general principle of HBOT is to deliver oxygen 
(O2) through the respiratory tract with an ambient pressure 
inside the chamber higher than atmospheric pressure. The 
therapeutic effects of HBOT result from two mechanisms, 
increasing the barometric pressure and the increasing O2 
partial pressure [2].
The first effect is purely mechanical and results from 
Boyle-Mariotte’s law, which evaluates the pressure (P) and 
volume (V) of a gas at a constant temperature (PV = k, 
k is a constant value). This effect can reduce the volume 
of an intravascular gas bubble in case of an iatrogenic gas 
embolism (IGE) or decompression sickness (DCS). 
The second effect of increasing the oxygen partial pres-
sure in the blood is important for HBOT. Increasing the 
dissolved O2 content can supplement defects in blood O2 
transport and accelerate denitrogenation. This also has 
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bacteriostatic and bactericidal effects on anaerobic germs 
[3]. Finally, HBOT can lead to a hyperoxic vasoconstriction, 
can limit inflammatory oedema and should have a rheologic 
effect by increasing the deformability of red cells [4]. 
Hyperbaric oxygen therapy is delivered during one 
session or repetitive sessions, the duration and maximal 
pressure of which vary according to the specific protocols 
of different hyperbaric centres and the disease being 
treated. Hyperbaric chambers (HCs) are controlled and 
supervised by qualified staff (hyperbaric medicine and 
intensive care medicine). HCs depend on Intensive Care 
Units (ICU) or specialised emergency departments to care 
for critically ill patients who need mechanical ventilation 
(MV), inotropic support or thoracic drainage (chest tube). 
MV for critically ill patients is possible inside a HC under 
certain conditions [5]. Precautions should be carefully tak-
en concerning the preparation of the patient, sedation and 
particularities based on material considerations because 
of the hyperoxic or explosive environment. Nevertheless, 
the literature lacks information on the epidemiology of ven-
tilated patients benefiting from HBOT [6]. Consequently, 
we aimed to investigate the epidemiology of patients who 
require MV during HBOT sessions.
MATERIALS AND METHODS
PURPOSE
We aimed to investigate the epidemiology of patients 
who require MV during HBOT sessions.
STUDy DESIgN AND PATIENTS
A prospective observational study was performed in 
a University Hyperbaric Centre in France from January 1, 
2005 to December 31, 2010. Garches is located in the Paris 
area and houses the only public HC for the entire region 
(12 million inhabitants). All of the consecutive intubated 
patients admitted for HBOT to our facility were prospectively 
enrolled during this 6-year period, regardless of age or dis-
ease. The hyperbaric therapy was almost always performed 
for acute injuries (DCS, CO poisoning, IGE, soft tissue in-
fection) and chronic injuries (wounds, osteoradionecrosis).
VENTILATION DEVICE USED
For the duration of the study, we used the French venti-
lator LAMA® (RCH, France) which is a rudimentary ventilator. 
This ventilator has a CE certification. However, it is no longer 
distributed, and repairing the ventilator is becoming more 
difficult. Only two other ventilators have a CE certifications 
in Europe for MV under hyperbaric conditions, the Siaretron 
1000 Iper® (Siare, Italy) and Servo-I® (Maquet, Sweden). 
The LAMA® is a volumetric ventilator with a pneumatic 
logic controlling inspiratory flow at a constant level. This 
ventilator is preset in a range of 3 to 21 L/min in 3 L/min 
steps. Positive end-expiratory pressure (PEEP) is adjustable 
up to 10 cmH2O. The last possible setting is the breath rate, 
which is in the range of 5 to 35 breaths/min in 5 breaths/ 
/min steps. The oxygen concentration cannot be resolved; 
it is 100% by default (Fig. 1). Finally, this ventilator can op-
erate only in the volume-controlled ventilation mode. It has 
an automatic compensation of tidal volume for hyperbaric 
conditions. Indeed, there is a normal increase of the gas 
density with compression during an HBOT session. Without 
this compensation mode, the user would have to change 
the tidal volume himself as the compression increased.
COLLECTION Of DATA
For every patient, we noted the sex, age, pathology, and 
positive inotropic support or MV required whenever needed. 
On a respiratory level, the relationship of the PaO2 (kPa) and 
FiO2, PEEP levels (cmH2O) and the presence or absence of 
acute respiratory distress syndrome (ARDS) were noted, 
according to the Berlin ARDS Definition [7]. Side effects 
have been reported. All of the data were collected with 
Excel® (Microsoft, Richmond, USA).
STATISTICAL ANALySIS
All statistical analyses were performed using statisti-
cal software (Statplus, AnalystSoft). All of the continuous 
variables are expressed as the means with standard devi-
ations. A Wilcoxon or Student’s test was performed. All of 
the categorical variables are expressed as numbers with 
percentages and a c2 test was used. A value of p < 0.05 
was considered statistically significant for all of the tests.
RESULTS
From 1 January 2005 to 31 December 2010, 1024 pa-
tients (for 1367 HBOT sessions) were admitted for HBOT, of 
whom 150 (14.65%) were mechanically ventilated (Fig. 2). 
Figure 1. The LAMA© ventilator
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Figure 2. Repartition of patients at admission in the hyperbaric 
unit; ARDS — acute respiratory distress syndrome; MV — mecha-
nical ventilation
Table 1. Base-line characteristics
Characteristics of patients MV with ARDS (n = 35) MV without ARDS (n = 91) P
Male/female sex-ratio 2.88 1.33 0.12
Age 50 [36;65.5] 59 [40.5;70.5] 0.22
Number of sessions 1 [1;1] 1 [1;1] 0.69
CO poisoning 23 (65.71%) 43 (47.25%) 0.097
IGE 7 (20%) 35 (38.46%) 0.079
Soft tissue infection 5 (14.29%) 12 (13.19%) 1.00
H2S poisoning 0 (0%) 0 (0%) –
ATPI 0 (0%) 0 (0%) –
DCS 0 (0%) 1 (1.09%) –
ARDS — acute respiratory distress syndrome; ATPI — acute traumatic peripheral ischaemia; CO — carbon monoxide; DCS — decompression sickness; IGE — iatrogenic gas 
embolism; MV — mechanical ventilation; H2S — hydrogen sulphide
Table 2. Clinical status of patients
Clinical status of patients ARDS+ (n = 35) ARDS– (n = 91) P
Norepinephrine 6 (17.14%) 25 (27.47%) –
Epinephrine 1 (2.85%) 3 (3.29%) –
Dopamine 1 (2.85%) 2 (2.19%) –
Norepinephrine/dobutamine 0 (0%) 1 (1.09%) –
Sedation with M alone 4 (11.43%) 8 (8.79%) –
Sedation with M/S 25 (71.43%) 60 (65.93%) –
Sedation with M/F 4 (11.43%) 11 (12.09%) –
Sedation with P/S 1 (2.86%) 4 (4.4%) –
Sedation with P alone 0 (0%) 4 (4.4%) –
Sedation with M/S/K 1 (2.86%) 0 (0%) –
Sedation with VP or N 0 (0%) 1 (1.1%) –
PEEP [cmH2O] 8 [5;10] 4 [0;5] <  0.0001
PaO2/FiO2 [kPa] 13.5 [10.25;22.1] 35.6 [28.5;48.2] <  0.0001
ARDS — acute respiratory distress syndrome; M — midazolam; S — sufentanil; F — fentanyl; P — propofol; K — ketamine; N — nesdonal; VP — sodium valproate;  
PEEP — positive end-expiratory pressure
The sex ratio was 1.72 (95 men), and the ages were 
ranged between 18 days of life and 94 (51 ± 21.9) 
years old. We divided the patients into three groups 
based on whether they required MV or not. Among the 
patients who required MV, we noted whether ARDS was 
present or not. 
Both Tables 1 and 2 show the baseline characteristics 
and clinical data of the patients. Severe carbon monoxide 
poisoning and IGE accounted for the majority of diagnoses 
leading to MV. However, patients with soft tissue infection 
are rarer but they are often critically ill and require MV too. 
Positive inotropic support was required in 28% of the pa-
tients because of shock. ARDS was present in 35 patients 
who were ventilated with the highest PEEP levels available 
in the HC (mean PEEP, 8 cmH2O).
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Table 3. Side effects
Side effects/Outcome MV with ARDS (n = 35) MV without ARDS (n = 91) P
Side effects 2 (5.71%) 13 (14.29%) 0.31
Major side effects 1 (2.86%) 6 (6.59%) –
   Seizures (2 IGE) 0 (0%) 2 (2.2%) –
   CPA (IGE, CO) 1 (2.86%) 1 (1.1%) –
   Shock (2 CO, 1 STI) 0 (0%) 3 (3.3%) –
Minor side effects 1 (2.86%) 5 (5.49%) –
   Dyssynchrony (3 CO, 2 IGE, 1 STI) 1 (2.86%) 5 (5.49%) –
   Middle-ear barotrauma 0 (0%) 0 (0%) –
Died in ICU 8 (22.86%) 7 (7.69%) 0.041
Died at hospital 8 (22.86%) 8 (8.79%) 0.068
ARDS — acute respiratory distress syndrome; CO — carbon monoxide poisoning; CPA — cardiopulmonary arrest; ICU — Intensive Care Units; IGE — iatrogenic gas embolism; 
MV — mechanical ventilation; STI — soft tissue infection
The complications data are shown in Table 3. First, 
6 (4.8%) patients presented with minor side effects, such 
as agitation and hallucinations, probably due to ketamine 
and inadequate sedation. The minor side effects were pa-
tient-ventilator asynchrony because of suboptimal sedation 
and environmental stress. Indeed, all of the patients, regard-
less of age, had been more or less sedated. Two patients 
presented with the major side effects of cardiopulmonary 
arrests (1.6%), 2 (1.6%) presented with epileptic seizures 
and 3 (2.4%) presented with severe shocks despite the use 
of inotropic drugs. The mortality in the ICU reached 23% in 
the ARDS group.
DISCUSSION
The main interest of our work was to present, for the first 
time and for a large panel of patients, the epidemiology of 
MV for patients requiring hyperbaric oxygenation treatment. 
Until this study, we did not know precisely why or how chil-
dren or adults were ventilated with HBOT.
WHICH PATIENTS NEED TO BE VENTILATED  
IN HyPERBARIC CHAMBERS?
Some patients need MV after certain injuries. In a few 
experimental cases, MV is the main treatment for con-
ditions such as iatrogenic gas embolism [8]. However, 
more often, MV is one part of a treatment plan, such as 
positive inotropic support or antibiotic therapy, for soft 
tissue infections or CO poisoning. Consequently, MV has to 
be performed before, during, and after an HBOT session. 
For the Undersea and Hyperbaric Medical Society (UHMS) 
and the European Committee for Hyperbaric Medicine 
(ECHM), HBOT is approved for IGE, DCS, carbon monoxide 
or cyanide poisoning, smoke inhalation, necrotizing soft 
tissue infections, crush injuries, compartment syndromes, 
acute traumatic peripheral ischaemia, enhancement of 
healing for selected wounds, refractory osteomyelitis and 
compromised skin flaps or grafts [1, 9]. In this work, we 
used HBOT for severe diseases, such as IGE, CO poisoning 
and necrotizing soft tissue infection. We have also used 
HBOT in 2 cases of severe H2S poisoning in children despite 
a lack of scientific evidence.
PATIENT’S PREPARATION
Because of the variations of atmospheric pressure 
(Boyle-Mariotte law’s stated in the mid — 1600 s that the 
absolute pressure and volume of a given mass of gas are 
inversely proportional at a constant temperature) during 
an HBOT session, saline is used to inflate the endotracheal 
tube’s (ETT) cuff for intubated patients. We routinely inject 
saline in the cuff to replace air before compression. Contrary 
to air or gases, liquids are not compressible during pressure 
variations, such as during increases (HBOT) or decreases 
in atmospheric pressure (flying above sea level). Based on 
our experience, we prefer saline to fill the cuffs, but others 
liquids can be used. Although saline should not be used to 
fill balloons of urinary catheters (crystallisation and valve 
malfunction), its use for ETT’s cuff filling is safe for a few 
hours. Sterile water should be used cautiously because of 
its irritating effect laryngotracheally in the case of a cuff 
rupture. We reported some bronchospasms in such cases 
[10]. Instead of performing a chest X-ray to look for a pneu-
mothorax before entering a HC, physician should perform 
a more relevant, non-invasive chest sonography to detect 
a pneumothorax [11–13].
SEDATION DURINg HBOT
Hyperoxia leads to peripheral vasoconstriction. Con-
sequently, under hyperbaric conditions, parenteral drugs 
absorption may be different from standard conditions. An 
intravenous infusion is the best way to administer drugs in 
Int Marit Health 2017; 68, 1: 46–51
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a HC. Syringe pumps are available for this specific use [14]. 
Sedation and analgesia of the intubated patient has to 
be optimal because of the many constraints that occur 
during an HBOT session: intra or interhospital transport, 
shaft handlings, noise, temperature variations (tempera-
ture increases during the compression phase, but falls 
during decompression), otalgia, ventilator tolerance, and 
postoperative pain surgery (necrotizing soft tissue infec-
tion). Usual sedation combining an opioid (fentanyl or 
sufentanil) with a hypnotic like midazolam or propofol is 
well adapted for hyperbaric conditions. In this study, 107 
(84%) patients received this type of sedation. Although all 
of the patients received sedation, 18 (14%) were probably 
wrongly sedated using midazolam, propofol or an antiepi-
leptic drug infused alone. Ketamine, antidepressants and 
neuroleptics were not used for continuous sedation in the 
hyperbaric environment. Only 2 children received ketamine 
during the study period. Halogen gases are avoided in this 
environment because they depend on a specific vaporiza-
tor that may lead to an electrical arc. Finally, neuromus-
cular blocker use is possible in association with sufficient 
sedation with the same advantages and disadvantages 
associated with its use in the ICU [15]. There are neither 
proven pharmacokinetic nor pharmacodynamic effects 
due to high pressure until 608 kPa (50 msw depth) for 
anaesthesia drugs [16].
CARE Of INTUBATED PATIENT
The compression of the HC and the solitary confine-
ment require attentive supervision of the patient. In the 
case of a quick ascent, it is almost impossible to take 
a patient out of the chamber in less than 10 min because 
of the risk of DCS for both the patient and caregiver. Con-
sequently, patients should be monitored, and their arterial 
pressure, heart beat and oxygen saturation should be 
frequently supervised. Moreover, patients seemed to be 
more and more seriously ill in our facility. MV and positive 
inotropic support have increased from 17% to 29% and 
from 7% to 19%, respectively, between 2005 and 2010. 
The head nurse should look for an asymmetric thoracic 
expansion during breathing and an absence of subcuta-
neous emphysema appearance because attentive lung 
auscultation is unrealistic with such background noise. To 
limit the hypercapnia risk for the patient, the tidal volume 
should be checked with the aid of calibrated spirometry 
or capnography that decreases with compression and 
is correlated to the PTCCO2 and PaCO2 [17, 18]. Neither 
Bis-spectral index monitoring nor clinical sedation-agitation 
scales have yet been evaluated under hyperbaric condi-
tions [19]. After an HBOT session and upon return to the 
ICU, an ETT cuff will be reinflated with air to avoid saline 
crystallisation and the risk of cuff rupture.
COMPLICATIONS AND SIDE EffECTS Of HBOT
The main adverse-effects of HBOT are barotraumas 
and claustrophobia. Claustrophobia is possible in awaked 
patients, especially in monoplace chambers that are forbid-
den and not used in France. However, it is still possible to 
propose sedation (benzodiazepine or neuroleptics) for these 
patients. Barotrauma is not uncommon, and is a concern in 
the middle ear (MEB), teeth, sinuses and lungs. Contrary to 
accepted ideas, a recent French study questioned the use 
of MV as a risk factor for an MEB [20]. MEB onset seems 
to depend on many parameters, such as the compression 
speed. There is a systematic evaluation for a pneumothorax 
before compression, but a classical chest X-ray is inade-
quate to evaluate for the presence of a small or anterior 
pneumothorax with certainty. We have known for a few 
years that chest ultrasonography and tomodensitometry 
are both better than a chest X-ray [11, 12]. Finally, inhaling 
high concentrations of oxygen under pressure may lead 
to a seizure (cerebral oxygen toxicity). The Paul Bert effect 
explains that oxygen may lead to a seizure when the oxygen 
partial pressure (ppO2) is up to 180 kPa [21]. We observed 
2 seizures during this study in IGE victims, but none in the 
other patients. However, IGE itself can lead to a seizure. 
Additionally, our HBOT protocol proposed a compression to 
3.8 absolute atmospheres, leading to a ppO2 that reached 
380 kPa. In our work, the mortality in the ARDS group is 23% 
which is not higher from noticed rates (11% to 87%) in the 
general literature, including all aetiologies [22].
CONCLUSIONS
Mechanical ventilation is a safe method for patients 
during HBOT and can be used routinely. In our experience, 
iatrogenic gas embolism, carbon monoxide poisoning and 
soft necrotizing tissue infection are the main injuries lead-
ing to ventilation. Patients in our hyperbaric centre seem 
to be more and more seriously ill. This demonstrates the 
necessary closeness between hyperbaric chambers and 
intensive care units.
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